A Safety and Efficacy Study of Bimatoprost in Men With Androgenic Alopecia (AGA)

Study Identifier
192024-084
CT.gov Identifier
NCT01904721
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Study Complete

Study Details

Medical Condition
  • Hair Loss - Other
    • Study Drug
  • Bimatoprost Solution 1
  • Bimatoprost Solution 2
  • Bimatoprost Vehicle
    • Phase
    Phase 2
    Sex
    Male
    Age
    18 - 49 Years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Mild to moderate male pattern baldness (androgenic alopecia) with ongoing hair loss for at least 1 year * Willingness to maintain same hair style, length and hair color during study * Willingness to have micro-dot-tattoo applied to scalp (Stage 2 only)
    Exclusion Criteria:
    * Drug or alcohol abuse within 12 months * HIV positive * Received hair transplants or had scalp reductions * Use of hair weaves, hair extensions or wigs within 3 months * Use of minoxidil (oral or topical) and/or low level light treatment "combs" for hair growth within the last 6 months, or expected use during the study * Application of topical steroids or nonsteroidal anti-inflammatory drugs (NSAIDs) to scalp within 4 weeks

    Protocol Summary

    This is a safety and efficacy study of bimatoprost in male subjects with androgenic alopecia (AGA).

    Study Locations

    Location
    Status
    Location
    Fridley, Minnesota, United States
    Status
    Not applicable